Clene (CLNN) News Today $4.53 -0.16 (-3.41%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Clene price target lowered to $83 from $86 at CanaccordNovember 14 at 7:27 PM | markets.businessinsider.comClene’s Strategic and Financial Strengths Justify Buy Rating Amid Promising ALS Therapeutic DevelopmentsNovember 14 at 4:08 AM | markets.businessinsider.comClene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsNovember 13, 2024 | markets.businessinsider.comClene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsNovember 13, 2024 | markets.businessinsider.comClene Announces Q3 2024 Results and ALS Drug ProgressNovember 13, 2024 | markets.businessinsider.comClene Announces Q3 2024 Results and ALS Drug ProgressNovember 13, 2024 | markets.businessinsider.comIBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA LeadershipOctober 25, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA LeadershipOctober 25, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor ConferencesOctober 21, 2024 | finance.yahoo.comIBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private PlacementsOctober 11, 2024 | finance.yahoo.comClene to Present at Upcoming October ConferencesOctober 9, 2024 | finance.yahoo.comIndependent Chairman of the Board of Clene David Matlin Buys 26% More SharesOctober 6, 2024 | finance.yahoo.comClene Inc. chief science officer purchases $97,432 in company stockOctober 3, 2024 | investing.comClene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3MOctober 3, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3MOctober 3, 2024 | finance.yahoo.comClene Inc. (NASDAQ:CLNN) Director David J. Matlin Buys 92,307 SharesOctober 3, 2024 | insidertrades.comIBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private PlacementsOctober 2, 2024 | finance.yahoo.comMark Mortenson Buys 20,512 Shares of Clene Inc. (NASDAQ:CLNN) StockOctober 2, 2024 | insidertrades.comClene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private PlacementsOctober 2, 2024 | theglobeandmail.comClene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt FacilityOctober 2, 2024 | stockhouse.comClene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq RulesSeptember 30, 2024 | globenewswire.comIBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA LeadershipSeptember 26, 2024 | finance.yahoo.comClene’s CNM-Au8 Shows Promise in ALS Treatment Despite Trial Setbacks: A Strong Buy RecommendationSeptember 19, 2024 | markets.businessinsider.comBuy Rating Justified by Regulatory Progress and Positive ALS Treatment Data for Clene’s CNM-Au8September 18, 2024 | markets.businessinsider.comClene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival DataSeptember 16, 2024 | globenewswire.comEF Hutton Initiates Coverage of Clene (CLNN) with Buy RecommendationSeptember 11, 2024 | msn.comClene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment ConferenceSeptember 5, 2024 | theglobeandmail.comClene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative DiseasesSeptember 5, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment ConferenceSeptember 4, 2024 | finance.yahoo.comIBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative DiseasesSeptember 3, 2024 | finance.yahoo.comBioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Management to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | msn.comClene to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comIBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire PodcastAugust 30, 2024 | finance.yahoo.comBioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative DiseasesAugust 30, 2024 | msn.comClene’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS TrialsAugust 24, 2024 | theglobeandmail.comIBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS TrialsAugust 24, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative ConditionsAugust 13, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative ConditionsAugust 13, 2024 | finance.yahoo.comIBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast EpisodeAugust 12, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast EpisodeAugust 9, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides UpdatesAugust 9, 2024 | finance.yahoo.comIBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.August 8, 2024 | globenewswire.comClene (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative NanotherapeuticsAugust 7, 2024 | theglobeandmail.comClene Inc. Q2 Loss Decreases, Beats EstimatesAugust 7, 2024 | markets.businessinsider.comClene Reports Second Quarter 2024 Financial Results and Recent Operating HighlightsAugust 7, 2024 | globenewswire.comClene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALSAugust 6, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Announces Participation in Canaccord Genuity 44th Annual Growth ConferenceAugust 6, 2024 | theglobeandmail.comClene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company ShowcaseAugust 5, 2024 | finance.yahoo.comClene Inc. (84C0.F)August 3, 2024 | au.finance.yahoo.comClene (NASDAQ:CLNN) Stock Quotes, Forecast and News SummaryJuly 25, 2024 | benzinga.com Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address There is a little known company that is changing warfare (Ad)With geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military. Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t CLNN Media Mentions By Week CLNN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLNN News Sentiment▼0.210.55▲Average Medical News Sentiment CLNN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLNN Articles This Week▼132▲CLNN Articles Average Week Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VTYX News Today CADL News Today OTLK News Today RPTX News Today CKPT News Today FTLF News Today GBIO News Today IPHA News Today CNTX News Today IVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLNN) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
